首页> 外文期刊>Disease models & mechanisms: DMM >Myh6-driven Cre recombinase activates the DNA damage response and the cell cycle in the myocardium in the absence of loxP sites
【24h】

Myh6-driven Cre recombinase activates the DNA damage response and the cell cycle in the myocardium in the absence of loxP sites

机译:MyH6驱动CRE重组酶在没有LOXP网站的情况下激活DNA损伤反应和心肌中的细胞周期

获取原文
           

摘要

ABSTRACT Regeneration of muscle in the damaged myocardium is a major objective of cardiovascular research, for which purpose many investigators utilize mice containing transgenes encoding Cre recombinase to recombine loxP-flanked target genes. An unfortunate side effect of the Cre-loxP model is the propensity of Cre recombinase to inflict off-target DNA damage, which has been documented in various eukaryotic cell types including cardiomyocytes (CMs). In the heart, reported effects of Cre recombinase include contractile dysfunction, fibrosis, cellular infiltration and induction of the DNA damage response (DDR). During experiments on adult mice containing a widely used Myh6-merCremer transgene, the protein product of which is activated by tamoxifen, we observed large, transient, off-target effects of merCremer, some of which have not previously been reported. On Day 3 after the first of three daily tamoxifen injections, immunofluorescent microscopy of heart sections revealed that the presence of merCremer protein in myonuclei was nearly uniform, thereafter diminishing to near extinction by Day 6; during this time, cardiac function was depressed as determined by echocardiography. On Day 5, peaks of apoptosis and expression of DDR-regulatory genes were observed, highlighted by 25-fold increased expression of Brca1 . Concomitantly, the expression of genes encoding cyclin-A2, cyclin-B2 and cyclin-dependent kinase 1, which regulate the G 2 /S cell-cycle transition, were dramatically increased (50- to 100-fold). Importantly, immunofluorescent staining revealed that this was accompanied by peaks in Ki67, 5′-bromodeoxyuridine and phosphohistone H3 labeling in non-CMs, as well as CMs. We further document that tamoxifen-induced activation of merCremer exacerbates cardiac dysfunction following myocardial infarction. These findings, when considered in the context of previous reports, indicate that the presence of merCremer in the nucleus induces DNA damage and unscheduled cell-cycle activation. Although these effects are transient, the inclusion of appropriate controls, coupled with an awareness of the defects caused by Cre recombinase, are required to avoid misinterpreting results when using Cre-loxP models for cardiac regeneration studies. This article has an associated First Person interview with the first author of the paper.
机译:摘要肌肉中肌肉再生损坏的心肌是心血管研究的一个主要目标,目的是许多研究人员利用含有编码CRE重组酶的转基因的小鼠重组Loxp侧翼靶基因。 CRE-LOXP模型的不幸副作用是CRE重组酶的倾向,以造成偏离靶DNA损伤,这些DNA损伤已被记录在包括心肌细胞(CMS)的各种真核细胞类型中。在心脏中,CRE重组酶的报告的作用包括收缩功能障碍,纤维化,细胞浸润和DNA损伤反应的诱导(DDR)。在含有广泛使用的MyH6-Mercremer转基因的成人小鼠的实验期间,由Tamoxifen激活的蛋白质产物,我们观察到Mercremer的大,瞬态,偏离目标效果,其中一些尚未报道。在第3天在三次每日他莫昔芬注射液中,心脏切片的免疫荧光显微镜显示,肌核中的Mercremer蛋白的存在几乎是均匀的,此后将在第6天的灭绝附近减少;在此期间,通过超声心动图确定,抑制心脏功能。在第5天,观察到凋亡的峰值和DDR调节基因的表达,突出显示BRCA1的表达25倍。同时,编码细胞周期蛋白-A2,细胞周期蛋白-B2和细胞周期蛋白依赖性激酶1的基因的表达,其调节G 2 / S细胞循环过渡,显着增加(> 50-至100倍)。重要的是,免疫荧光染色显示,这伴随着在非CMS中的Ki67,5'-溴酰基脲酰胺和磷酸核苷酸H3标记的峰,以及CMS。我们进一步记载了他莫昔芬诱导的Mercremer激活的文献使心肌梗死后的心脏功能障碍加剧。在先前报告的上下文中考虑时,这些发现表明核中的摩擦器的存在诱导DNA损伤和未安排的细胞周期激活。虽然这些效果是瞬态的,但包括适当的对照,同时加上CRE重组酶引起的缺陷的认识,以避免使用CRE-LOXP模型进行心脏再生研究时避免误解结果。本文有一个相关的第一人称采访本文的第一个作者。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号